NCT07467161

Brief Summary

The primary aim of the study is to evaluate the association between vitamin D levels and triglyceride-glucose index as a marker of insulin resistance in patients with type 2 DM.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started Mar 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress15%
Mar 2026Mar 2028

Study Start

First participant enrolled

March 1, 2026

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

March 8, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 12, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Last Updated

March 13, 2026

Status Verified

March 1, 2026

Enrollment Period

1.8 years

First QC Date

March 8, 2026

Last Update Submit

March 11, 2026

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

  • Impact of vitamin D level on insulin resistance

    Evaluation of the association between vitamin D levels and triglyceride-glucose index as a marker of insulin resistance in patients with type 2 DM

    baseline

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with type 2 DM

You may qualify if:

  • Patients with type 2 DM diagnosed based on American Diabetes Association criteria.

You may not qualify if:

  • Patients with type 1 DM or other types of diabetes.
  • Patients with complications of acute DM.
  • Pregnant females.
  • Malignancy.
  • BMI \> 35 kg/m²
  • Major co-morbidities as end-stage renal disease or liver cell failure.
  • Patients on lipid lowering therapy.
  • Patients on vitamin D supplementation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022 Jan;46(1):15-37. doi: 10.4093/dmj.2021.0280. Epub 2021 Dec 30.

    PMID: 34965646BACKGROUND

  • Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, Sowers JR. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021 Jun;119:154766. doi: 10.1016/j.metabol.2021.154766. Epub 2021 Mar 22.

    PMID: 33766485BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

Sara Magdy Ahmed Mohammed, MD

CONTACT

+201098777997dr.sara54.sm@gmail.com

Hanaa Mohamed Riad, MD

CONTACT

+201094608083hanaaried@aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer

Study Record Dates

First Submitted

March 8, 2026

First Posted

March 12, 2026

Study Start

March 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

March 1, 2028

Last Updated

March 13, 2026

Record last verified: 2026-03